Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HINT1 | P49773 | 5/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | PNP | P00491 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601879 | 1.00 | HPGD (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL28911220 | 0.92 | HINT1 (0.60) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL16360143 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12031119 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL222316 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL18512866 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL26515 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL16198946 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL3713950 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12300426 | 0.92 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | IVERIC BIO, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4374873-A2 | METHODS FOR TREATING OR PREVENTING OPTHALMOLOGICAL CONDITIONS | IVERIC bio, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20230364123-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364122-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220175813-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210369757-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IVERIC BIO, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3628373-A1 | METHODS FOR TREATING OR PREVENTING OPTHALMOLOGICAL CONDITIONS | IVERIC bio, Inc. (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3194029-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | Ophthotech Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3165606-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160296550-A1 | Methods for Treating or Preventing Ophthalmological Conditions | IVERIC BIO, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20150182623-A1 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist | Integrity Bio, Inc. | 2015-07-02 | — | — | US | disclosed |
| US-20150157709-A1 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist | Integrity Bio, Inc. | 2015-06-11 | — | — | US | disclosed |
| EP-2854844-A2 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | Ophthotech Corporation (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2015006734-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | OPHTHOTECH CORPORATION (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | OPHTHOTECH CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013181495-A2 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | OPHTHOTECH CORPORATION (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130323242-A1 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | OPHTHOTECH CORP. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120100136-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2432476-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010127029-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | VEGFA, PDGFA, PGF | HPGD 457/4885HINT1 4290/4885NT5E 1112/4885 |
| US-20210369757-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885NT5E 75/4885 |
| US-20220175813-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885NT5E 75/4885 |
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885NT5E 75/4885 |
| US-20160296550-A1 | Methods for Treating or Preventing Ophthalmological Conditions | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885NT5E 75/4885 |
| US-20230364122-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | IL5, HDAC5, MC5R | HPGD 613/4885HINT1 3370/4885NT5E 293/4885 |
| US-20230364123-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | ADCY5, MC5R, C5 | HPGD 709/4885HINT1 1792/4885NT5E 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.